Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 24:11:1376645.
doi: 10.3389/fcvm.2024.1376645. eCollection 2024.

Impact of sodium-glucose cotransporter-2 inhibitor use on peak VO2 in advanced heart failure patients

A Desai  1 , S Sharma  1 , N Abuah  1 , J Jang  1 , S Desai  1 , S Paghdhar  1 , R M Goswami  1
Affiliations

Impact of sodium-glucose cotransporter-2 inhibitor use on peak VO2 in advanced heart failure patients

A Desai et al. Front Cardiovasc Med. .

Abstract

Introduction: Advanced heart failure (HF) is an epidemic that affects multiple organ systems with high morbidity and mortality rates despite optimal medical therapy (OMT) and remains the leading cause of hospitalizations in type 2 diabetes-related cardiovascular disease. The addition of sodium-glucose co-transporter inhibitors (SGLT2i) in treating these patients has seen improved mortality and hospital admission rates. As such, we felt it was important to investigate whether the use of SGLT2i improved functional capacity in patients with HF when compared to OMT by evaluating maximum oxygen consumption (peak VO2) using cardiopulmonary exercise testing (CPET).

Methods: We found 94 heart failure patients between August 2020 and August 2021 who underwent CPET before and after treatment at Mayo Clinic in Florida. 50 patients received OMT and 44 received OMT and SGLT2i therapy. CPET results before and after were compared for each group.

Results: The baseline ejection fraction was not significantly different between groups, with the OMT group at 38% and the SGLT2i group at 33%, p = 0.10. OMT patients were found to have a significantly lower hemoglobin A1c of 5.7 (5.4-6.1) compared to those with SGLT2i therapy of 6.4 (5.8-7.1), p = 0.01. The baseline peak VO2 was 17.3 ml/kg/min (13.3-21.6) in the OMT group and 17.3 ml/kg/min (14.4-18.9) in the SGLT2i group, p = 0.18, not significantly different. The interesting finding is that the follow-up peak VO2 at one year for the OMT group was 17 ml/kg/min (13.3-21.6), which was not significantly different from the SGLT2i group peak VO2 of 17 ml/kg/min (14.6-19.6), p = 0.19. Our study is the first to compare before and after peak VO2 values of the OMT+SGLT2i group to the patient's own baseline and we found no significant improvement.

Conclusion: Our single-center data shows no improvement in functional capacity after the addition of SGLT2i therapy to OMT in patients with advanced heart failure. Improved hospitalization and symptoms may be attributed to other numerous effects of SGLT2i such as volume management.

Keywords: CPET; SGLT2i; VO2; diabetes; exercise test; functional capacity; heart failure; transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
NSGLT2i and their role in exercise tolerance. LVESV, left ventricular end systolic volume; LVEF, left ventricular ejection fraction.
Figure 2
Figure 2
Standard CPET performed using modified ACIP protocol. CPET, cardiopulmonary exercise test; ACIP, Asymptomatic Cardiac Ischemia Pilot.
Figure 3
Figure 3
Statistical difference between and within the two study groups.
Figure 4
Figure 4
Peak VO2 before and after in the OMT and the OMG+SGLT2i group.
Figure 5
Figure 5
Baseline peak VO2 and individual PERCENT CHANGE in peak VO2 at follow-up in both study groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bonora BM, Vigili de Kreutzenberg S, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. Cardiovasc Diabetol. (2019) 18:106. 10.1186/s12933-019-0910-5 - DOI - PMC - PubMed
    1. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. (2017) 136(17):1643–58. 10.1161/CIRCULATIONAHA.117.030012 - DOI - PMC - PubMed
    1. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. (2020) 383(15):1413–24. 10.1056/NEJMoa2022190 - DOI - PubMed
    1. Voorrips SN, Saucedo-Orozco H, Sánchez-Aguilera PI, De Boer RA, Van der Meer P, Westenbrink BD. Could SGLT2 inhibitors improve exercise intolerance in chronic heart failure? Int J Mol Sci. (2022) 23(15):8631. 10.3390/ijms23158631 - DOI - PMC - PubMed
    1. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. (1991) 83(3):778–86. 10.1161/01.CIR.83.3.778 - DOI - PubMed

LinkOut - more resources